Understand the source comparison
Peptide Laws Australia TGA Regulations: Schedule 4 vs Unscheduled
Semaglutide (Ozempic) Schedule 4 Special Access Scheme Category B approval OR Section 19 research permit Prescription-only; cannot be sold without ARTG registration High regulatory burden. TGA approval required for any import; compounding pharmacies cannot leg
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Ozempic)
- Schedule 4
- Special Access Scheme Category B approval OR Section 19 research permit
- Prescription-only; cannot be sold without ARTG registration
- High regulatory burden. TGA approval required for any import; compounding pharmacies cannot legally supply without SAS authorisation
- MK 677 (Ibutamoren)
- Section 19 import permit required
- Unregistered therapeutic good; research use only
- Frequently misclassified as 'supplement' by overseas suppliers; customs seizure common if import permit missing
- BPC-157
- Schedule 4 (as of March 2025)
- Research use only; no legal therapeutic supply pathway
- Recent rescheduling caught many suppliers off-guard; shipments without permits now seized automatically
- Thymalin
- Unscheduled
- Section 19 import permit recommended
- Can be imported for research; cannot be marketed for human consumption
- Lower scrutiny but still requires documentation; residential delivery without research affiliation triggers investigation
- Cerebrolysin
- Section 19 import permit required if >3 months' supply
- Research or personal import allowed under TGA personal importation scheme
- Technically unscheduled but peptide content triggers therapeutic goods classification
- Dihexa
- Research use only
- No therapeutic approval pathway exists; purely research chemical under current framework